GlassScriptPhysician profile
Obrad Kokanovic
NPI 1528358660
$45,627.32
in general payments reported to CMS, 2019-2025
15 companies · $43K in 2025
The $43K reported for 2025 was more than what 96% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2021: $20.42 · 2022: $378 · 2023: $286 · 2024: $1,589 · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $38K · Travel and Lodging: $5,297 · Food and Beverage: $2,135 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $37,500.00 |
| Travel and Lodging | $5,297.01 |
| Food and Beverage | $2,135.29 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $39,756.70 | 2021-2025 | Mitraclip, Triclip, Diamondback Coronary |
| Edwards Lifesciences Corporation | $2,914.71 | 2024-2025 | Sapien 3 Ultra Resilia, Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $1,245.72 | 2019-2025 | Versacross Connect Laac Access Solution |
| W. L. Gore & Associates, INC. | $524.16 | 2025 | Gore Cardioform Septal Occluder |
| Medtronic, INC. | $436.28 | 2023-2024 | Corevalve Evolut R, Onyx Frontier |
| E.R. Squibb & Sons, L.L.C. | $160.71 | 2019-2022 | |
| Acist Medical Systems, INC. | $146.29 | 2025 | |
| Janssen Scientific Affairs, LLC | $123.30 | 2022 | |
| Pfizer INC. | $110.30 | 2019 | |
| Medicure Pharma INC. | $70.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.26 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $30.58 | 2023 | Brilinta |
| Chiesi USA, INC. | $21.53 | 2023 | Kengreal |
| Lantheus Medical Imaging, INC. | $17.36 | 2022 | |
| Merck Sharp & Dohme LLC | $14.33 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obrad Kokanovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.